Scoping Review of Human Longitudinal Studies of Biomarkers Associated with Risk of Developing Systemic Lupus Erythematosus (SLE) to Inform the Development of a Novel SLE Risk Stratification Index
Alice Horisberger,
Youngmin Kim,
Jeong Yee,
Jacob J.E. Koopman,
Sindhu R Johnson,
Alí Duarte‐García,
Zahi Touma,
Marta Mosca,
Karen H. Costenbader Arthritis Care and Research
· Wiley
· 2026-11-11
· DOI: 10.1002/acr.80204
Аннотация
Objective SLE is often preceded by a preclinical phase in which autoantibodies and other biomarkers are detectable, offering an opportunity to identify at‐risk individuals for early monitoring and testing interventions to halt progression. To inform an effort to develop SLE risk‐stratification criteria, we conducted a scoping review of longitudinal human studies of biomarkers measured before SLE onset. Methods Following PRISMA‐ScR, we searched three databases and used a Population, Exposure, Comparator, Outcome framework to select longitudinal studies in which biomarkers were measured before an incident diagnosis or classification of SLE. Study characteristics, biomarkers, and outcomes were extracted from included studies. Results We included 59 original studies and two meta‐analyses including heterogeneous at‐risk populations, in which the proportion progressing to SLE varied widely. Most evidence concerned conventional serological markers, whereas interferon and cytokine signatures, proteomic panels, and genetic risk scores were examined in fewer, recent cohorts. Few biomarkers were studied across multiple populations or with comparable follow‐up, outcome definitions, and analytic methods, and most associations came from single studies without external validation. Longitudinal biomarker trajectories before onset were rarely characterized, and non‐European populations were under‐represented. Conclusion his review maps the breadth of candidate biomarkers associated with the risk of developing SLE and the heterogeneity of the evidence supporting them. Building a clinically useful SLE risk‐stratification index will need a shared definition of the at‐risk state, and prospective studies that follow biomarkers over time, in populations from broader geographical regions.
Alice Horisberger, Youngmin Kim, Jeong Yee, Jacob J.E. Koopman, Sindhu R Johnson, Alí Duarte‐García et al. Scoping Review of Human Longitudinal Studies of Biomarkers Associated with Risk of Developing Systemic Lupus Erythematosus (SLE) to Inform the Development of a Novel SLE Risk Stratification Index. // Arthritis Care and Research. – 2026. – DOI: 10.1002/acr.80204. – URL: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.80204?af=R
Alice Horisberger, Youngmin Kim, Jeong Yee, Jacob J.E. Koopman, Sindhu R Johnson, Alí Duarte‐García, Zahi Touma, Marta Mosca, & Karen H. Costenbader (2026). Scoping Review of Human Longitudinal Studies of Biomarkers Associated with Risk of Developing Systemic Lupus Erythematosus (SLE) to Inform the Development of a Novel SLE Risk Stratification Index. Arthritis Care and Research. https://doi.org/10.1002/acr.80204
Alice Horisberger, et al. “Scoping Review of Human Longitudinal Studies of Biomarkers Associated with Risk of Developing Systemic Lupus Erythematosus (SLE) to Inform the Development of a Novel SLE Risk Stratification Index.” Arthritis Care and Research, 2026. doi:10.1002/acr.80204.
@article{Horisberger2026,
title = {Scoping Review of Human Longitudinal Studies of Biomarkers Associated with Risk of Developing Systemic Lupus Erythematosus (SLE) to Inform the Development of a Novel SLE Risk Stratification Index},
author = {Horisberger, Alice and Kim, Youngmin and Yee, Jeong and Koopman, Jacob J.E. and Johnson, Sindhu R and Duarte‐García, Alí and Touma, Zahi and Mosca, Marta and Costenbader, Karen H.},
journal = {Arthritis Care and Research},
year = {2026},
doi = {10.1002/acr.80204},
url = {https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.80204?af=R}
}
Objective Black patients with systemic sclerosis (scleroderma) have more severe disease than White patients. We investigated whether racial differences in therapeutic responses to mycophenolate mofetil (MMF) could explain this...